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Progressive vs Non-Progressive Onset of Chronic GVHD
After ATG Prophylaxis Is Highly Predictive of Outcome
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The NIH chronic graft versus host disease (cGVHD) consensus
statement emphasizes the importance of distinguishing
acute from cGVHD based on clinical features rather than
time. The proposed assessment of cGVHD severity appears to
be prognostically important, but the relevance of categories
and type of onset remains controversial. We retrospectively
analyzed a homogeneously treated population of 600
patients transplanted between 1999-2010 with ﬂudarabine
50 mg/m2 daily X 5, IV busulfan 3.2 mg/kg daily x 4, ATG
(Thymoglobulin, Genzyme - total dose of 4.5 mg/kg). An
additional 287 patients (48%) received additional TBI 200cGy
x 2. In this cohort, 245 patients (47%) had non-progressive
cGVHD (NP-cGVHD) arising either de novo (n ¼ 221) or after
stopping primary immunosuppression (n ¼ 24). In 71
patients (12%) progressive cGVHD (P-cGVHD) arose during
systemic therapy for grade II-IV acute GVHD and 284 (41%)
had no cGVHD. Patient and transplant factors were similar
across all groups. Median followup was 84 (range 22- 161)
months. The 5-year non-relapse mortality was 40% for
patients with P-cGVHD compared with 11% for NP-cGVHD (P
< .0001) and 12% for no cGVHD (P < .0001). Patients with no
cGVHD had more relapse (38%) than those with P-cGVHD
(28%,P ¼ .02) and P-cGVHD (27%,P ¼ .002). Overall survival
for patients with no cGVHDwas 61% vs 50% for P-cGVHD (P¼
.005) and 69% for NP-cGVHD (P ¼ .02). Disease free survival
was 54% vs 43% (P ¼ .003) and 65% (P ¼ .003), respectively.
The median time on systemic immunosuppression for the
174 NP-cGVHD patients (71%) who required treatment was
273 days versus 398 days for all patients with P-cGVHD (p ¼
ns). In conclusion, we propose that this simple means of
classifying cGVHD is highly predictive of important trans-
plant outcomes. It remains important both to prevent acute
GVHD (and thus P-cGVHD) and yet take advantage of the
graft-vs-malignancy effect conferred by NP-cGVHD.438
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kine and chemokine dysregulation that predicts and also
contributes to disease severity. Intermediates in sulfur amino
acid (SAA) metabolism are known to modulate cytokines
implicated in GVHD, such as TNF-a and IL-2. In this ﬁrst
report, plasma and hepatic SAAs and other amino acid
metabolite concentrations were sequentially proﬁled using
redox metabolomics assay, in experimental allogeneic bone
marrow transplantation (Allo-BMT)models and compared to
syngeneic (Syn) BMT. At day +4, prior to increase in plasma
TNF-a and subsequent GVHD histopathological changes,
a signiﬁcant decline in both plasma and hepatic glutathione
(GSH) concentrations occurred resulting in a more oxidized
redox potential in Allo BMT (Balb/C B6), relative to Syn BMT
(B6Thy1.1 B6) mice. The plasma free GSH concentrations in
allogeneic mice were signiﬁcantly lower (w65%; P < .005)
when compared to Syn BMT controls and were accompanied
byw 3 fold increase (P¼ .012) in plasma GSSG. Paradoxically,
the plasma concentration of total cysteine, which is the rate-
limiting substrate for GSH synthesis, was signiﬁcantly higher
in Allo BMT versus Syn BMT mice at day +10 suggesting that
loss in GSH was not due to substrate limitation. Signiﬁcant
difference in the GSSG/GSH ratio was also noted in Allo /
GVHD+ compared to Allo/GVHD- in un-irradiated paternal to
F1 hybrid transplantation model (B6  B6D2F1), indicating
that GSH depletion was a metabolic event associated with
GVHD, and not a consequence of conditioning regimen
(0.3150  0.06007 vs 17.00  4.907, respectively, p¼0.0145).
At day+10, metabolomic proﬁle was able to segregate Allo/
GVHD+ from Allo/GVHD- based on hepatic total GSH, free
GSH and total cystinylglycine concentration. The plasma
TNF-a elevation lagged behind redox changes with no
signiﬁcant difference detected in Syn-BMT and Allo-BMT
group at day +4. Hepatic GCLC mRNA abundance, regulated
by Nrf2 transcription factor, was decreased by w50% (P <
.0001) at day +4 and further declinedw80% by Day +10 (P <
.0004), in Allo BMT compared to Syn BMT. Interestingly,
hepatic nuclear Nrf2 and TNF-a concentrations at Day +10
were inversely correlated (r2¼0.8,P ¼ .01) in Allo-BMT.
Modulation of GSH in mixed lymphocyte culture using GSH
depleting agents, buthionine sulfoximine and diethyl mal-
eate, increased TNF-a expression in CD4 T cells compared to
untreated controls (P < .001). These experiments show the
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We have shown that costimulation blockade can protect
against acute GvHD (aGvHD) in a non-humanprimatemodel.
We therefore designed a ﬁrst-in-disease trial of in vivo
CD28:CD80/86-directed costimulation blockadewith CTLA4-
Ig (abatacept) to prevent aGvHD after unrelated-donor HSCT
for patients > 12y. In this trial, 10mg/kg abatacept was
administered IV on day -1, +5, +14, +28 in addition to stan-
dard prophylaxis with cyclosporine + MTX.
Patient Characteristics and Survival: 10 patients, with
a median age of 44.5 y (17-74) were enrolled and treated. 6
received 7/8-matched and 4 received 8/8-matched URD
HSCT. 8 received PBSCs and 2 received BM. All received high-
intensity conditioning. With a median follow-up of 367 days
(262-680), 7 patients are alive and in remission and 2
patients died of relapse. One patient died, in remission, of
trauma-related multi-organ failure > 1yr post-transplant.
Feasibility, Pharmacokinetics and Pharmacodynamics:
All 10 patients received all scheduled abatacept doses,
without infusion reactions. The average peak (230.9 +/- 7.4
mg/ml) and trough (45.9 +/- 2.8 mg/ml) abatacept levels, as
well as the terminal T1/2 (19.6 +/- 1.9 days) were similar to
healthy controls. Importantly, as has been established in
vitro, patients receiving abatacept demonstrated signiﬁcant
inhibition of post-transplant CD4+ T cell proliferation (with
>80% reduction of Ki-67+ proliferating CD4+ T cells at d +28
compared to controls not receiving abatacept, Figure 1A).
Figure 1A. Patients Treated with Abatacept Exhibit Fewer Proliferating CD4+
T Cells After Transplant. Black: Control patients treated with cyclosporine/
MTX alone (n¼6), Red: Patients treated with cyclosporine/MTX + Abatacept
(n ¼ 10)
Engraftment: All patients achieved neutrophil engraftment
(median d+16.5) and donor engraftment (100% CD33
chimerism at d+30). Lymphocyte recovery was rapid: Day
+100 counts showed ALC¼ 1053 +/- 259 cells/ml, total T cells
¼ 741 +/- 208 cells/ml, and CD8+ T cells¼ 381 +/- 99 cells/ml.
The Day +100 CD4+ T cells ¼ 285 +/- 105 cells/ml, not
signiﬁcantly different from historical controls (n ¼ 43) that
received CNI/MTX aGvHD prophylaxis without abatacept
(262 +/-26 cells/ml).
GvHD: Patients receiving the abatacept-containing regimen
had encouragingly low rates of early severe aGvHD: Two
patients developed aGvHD before day +100, with one of
these patients (Gr II) progressing to steroid-dependent
cGvHD of the liver and one patient (Gr III) with resolution of
aGvHD. The cumulative incidence of grade II-IV and III-IV
aGvHD by day +100 was thus 20% and 10%, respectively
(Figure 1B). Importantly, there was no Gr IV aGvHD, no
patient received salvage therapy for aGvHD, and there were
no deaths from aGvHD.Figure 1B. Cumulative Incidence of Grade II-IV aGvHD (left) and Gr III-IV
aGvHD (right) In Patients Through Day +100 on the Abatacept Trial. No Grade
IV aGvHD developed.
Conclusions: This trial demonstrates, for the ﬁrst time, the
feasibility of adding in vivoTcell costimulation blockadewith
abatacept for aGvHD prevention. The decreased CD4+ T cell
proliferation post-transplant and the encouragingly low rates
of early, severe aGvHD suggest that costimulation blockade
may be an effective agent for aGvHD prophylaxis and support
the conduct of a larger, randomized phase 2 study.440
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We have developed a systems-biology approach to studying
GvHD, using whole-transcriptome analysis of pathogenic T
cells. Using computational methods, we have identiﬁed, for
the ﬁrst time, the transcriptional networks that drive
primate GvHD, and that lead to its partial control through
mTOR inhibition with sirolimus.
Methods: CD3+/CD20- T cells were puriﬁed ﬂow cytometri-
cally from 4 cohorts: (1) Healthy Controls (HC n ¼ 15); (2)
Auto-HSCT recipients (n ¼ 3); (3) Untreated Allo-HSCT
recipients who developed severe GvHD, (GvHD n ¼ 4); and
(4) Allo-HSCT recipients receiving sirolimus alone (Sirolimus
n ¼ 4). Puriﬁcation of T cells and RNA was followed by
primate-speciﬁc Affymetrix Gene Array analysis.
Computation: Gene array signals were processed using the
Robust Multichip Averaging Method. Principal Component
Analysis (PCA) revealed that variation was primarily deter-
mined by the experimental cohort (Figure 1A). This result
was critical, and conﬁrmed that transcriptomics could be
applied to identify genes and pathways controlling GvHD.
Differentially expressed genes (DE) were deﬁned, yielding
unique and overlapping gene signatures, with 775 DE genes
between GvHD and HC and 286 DE genes between Sirolimus
and HC (Figure 1B). Finally, using Ingenuity Pathway Analysis
(IPA) we characterized gene signatures according to molec-
ular pathways (Figure 1C).
Results: T cells from animals with severe aGvHD showed
transcriptional signs of rampant proliferation and cytotox-
icity, but also of cell death. IPA identiﬁed highly statistically
signiﬁcant upregulation of Cell Cycle as well as Cell Traf-
ﬁcking and Inﬂammatory Response networks (Figure 1C, P <
.001) These networks contained some expected genes and
some surprises. Thus, GvHD was associated with upregula-
tion of JAK and IFN signaling ( P < .001), but unexpectedly,
was also associated with upregulation of the Sonic Hedgehog
